Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated advanced ovarian cancer remain disease free after five years, a new study shows.
Sep 21, 2020
0
3
(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according ...
Dec 19, 2019
0
0
The results from the major phase III OlympiA trial shows the drug improves survival rates in women who have inherited faults in their BRCA1 or BRCA2 genes.
Mar 17, 2022
0
23
(HealthDay)—One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant ...
Jul 9, 2021
0
2
Studies have shown that utilizing a PARP inhibitor in the management of patients with metastatic pancreatic cancer who harbor BRCA 1/2 mutations is clinically beneficial. New research in the November 2020 issue of JNCCN—Journal ...
Nov 12, 2020
0
1
Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented at a Seminal Session during the Society for Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer in March 2022. The analysis, which ...
Mar 21, 2022
0
4
A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings ...
Sep 30, 2019
0
1
Men with hormone-resistant prostate cancer and specific genetic mutations who were treated with the PARP inhibitor drug olaparib survived longer than men treated with traditional hormone therapy, according to an analysis ...
Dec 7, 2023
0
1
